Thank you, Mr. Chair and members of the committee.
My name is Dave Prowten. I am the president and CEO of JDRF Canada. I am joined today by Patrick Tohill.
I'd like to begin by thanking you for undertaking this important study. We're especially grateful to Ms. Sidhu for bringing this issue forward.
JDRF Canada is the world's leading charity focused on research to cure, prevent, and treat type 1 diabetes, a potentially fatal autoimmune disease in which a person's pancreas stops producing insulin, making them dependent on daily injections or infusions of insulin for life.
We say type 1 diabetes, or T1D, to distinguish from type 2, a disease in which the body continues to produce insulin but can no longer use it properly. T1D used to be known as juvenile diabetes, but today 85% of those living with type 1 are adults, and 20% are actually diagnosed as adults.
T1D impacts your life 24 hours a day, seven days a week, 365 days a year. It truly is a relentless disease. Food intake, physical activity, and insulin must be carefully balanced to maintain blood glucose levels within a target range. Failure to do so can result in costly and devastating complications.
As I'm sure you know, Canada has a rich legacy of innovation in type 1 diabetes research, from the world-changing discovery of insulin by Banting and Best to the Edmonton protocol for islet transplantation. JDRF is proud to have recently partnered with the Government of Canada to advance this research through the $30-million JDRF-CIHR partnership to defeat diabetes. We'd like to extend a hearty thanks for this support.
Looking to type 1 anti-diabetes strategies abroad, we note that the United States contributes $150 million U.S. annually to type 1 diabetes research. Australia has contributed $35 million over the past five years, and very recently, in the last month, made a nine-year $125-million commitment.
This is a very expensive disease for families and patients. Australia provides support towards the cost of managing the disease by reimbursing the costs of needles, test strips, and consumables. Continuous glucose monitors are provided to children under 21 and insulin pumps to children in low-income families.
Israel also provides reimbursement for diabetes devices, and provides free insulin as well.
In Canada, only Ontario, Alberta, and the three territories provide insulin pumps to people of all ages. In all other provinces these programs end at age 18, 19, or 25. Frankly, we have very poor coverage of continuous glucose monitors, and this technology has proven to be beneficial to Canadians to make their care better and easier.
At the federal level, we'd like to propose five recommendations today, which we hope you will consider in your report.
The first is that the government work with diabetes organizations and other stakeholders, as my colleagues from Diabetes Canada articulated, to develop a national diabetes strategy.
The second is that we create a national diabetes registry of all patients with type 1 diabetes. Registries such as those found in Australia, Scotland, Sweden, and the U.S. are improving our understanding of the epidemiology of diabetes and the effectiveness and value of interventions, which ultimately improve patient outcomes and reduce our health care costs.
Our third request is to permanently fix those issues that led to Canadians with type 1 diabetes being denied access to the disability tax credit and registered disability savings plan. Since December, when the Minister of National Revenue announced that diabetes claims would be reassessed, we've been hearing from grateful supporters whose previously denied claims are now being approved.
JDRF is committed to working with the government and the newly created disability advisory committee. Type 1 diabetics have qualified, since insulin is considered a life-sustaining therapy. We're recommending three key changes going forward. First, it must be recognized that carbohydrate calculation is integral to insulin dosage calculation. Second, the number of hours per week should be reduced from 14 to 10. Finally, RDSPs of those who have at one time qualified for the DTC should be protected so that they can't be clawed back if one's DTC status changes.
A fourth recommendation relates to the government's recently announced plan to study the creation of a national pharmacare program. It would be a missed opportunity, on the eve of the 100th anniversary of the discovery of insulin in Canada, if the various types of insulin were not included among drugs covered under pharmacare.
Our final and most important recommendation is to encourage the government to make significant investments in cure and prevention research. We're getting closer to the time of understanding how this autoimmune disease works. Stopping the immune attack on a body's insulin-producing cells and restoring the ability to produce insulin are of the utmost importance to eradicating type 1 diabetes. Imagine a future in which a Canadian developed a vaccine so that no one would ever get type 1 diabetes again. It is possible.
In closing, I'd like to thank the committee for this opportunity. We look forward to any questions you may have.